Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients.
Reeder JA, Creech CB, Nation RL, Gu K, Nalbant D, Wu N, Jimenez-Truque N, Fissell W, Rolsma SL, Fishbane N, Kirkpatrick CMJ, Patel PC, Watanabe A, Landersdorfer CB, Winokur P, An G. Reeder JA, et al. Among authors: nation rl. J Clin Pharmacol. 2024 Dec 3. doi: 10.1002/jcph.6161. Online ahead of print. J Clin Pharmacol. 2024. PMID: 39628093
Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Cystic Fibrosis.
Rolsma SL, Sokolow A, Patel PC, Sokolow K, Jimenez-Truque N, Fissell WH, Ryan V, Kirkpatrick CM, Nation RL, Gu K, Teresi M, Fishbane N, Kontos M, An G, Winokur P, Landersdorfer CB, Creech CB. Rolsma SL, et al. Among authors: nation rl. J Infect Dis. 2024 Sep 30:jiae451. doi: 10.1093/infdis/jiae451. Online ahead of print. J Infect Dis. 2024. PMID: 39344185
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
Breen SKJ, Harper M, López-Causapé C, Rogers KE, Tait JR, Smallman TR, Lang Y, Lee WL, Zhou J, Zhang Y, Bulitta JB, Nation RL, Oliver A, Boyce JD, Landersdorfer CB. Breen SKJ, et al. Among authors: nation rl. Int J Antimicrob Agents. 2024 Jun;63(6):107161. doi: 10.1016/j.ijantimicag.2024.107161. Epub 2024 Mar 30. Int J Antimicrob Agents. 2024. PMID: 38561094 Free article.
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
Tait JR, Harper M, Cortés-Lara S, Rogers KE, López-Causapé C, Smallman TR, Lang Y, Lee WL, Zhou J, Bulitta JB, Nation RL, Boyce JD, Oliver A, Landersdorfer CB. Tait JR, et al. Among authors: nation rl. Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0041423. doi: 10.1128/aac.00414-23. Epub 2023 Jul 10. Antimicrob Agents Chemother. 2023. PMID: 37428034 Free PMC article.
Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Agyeman AA, López-Causapé C, Rogers KE, Lucas DD, Cortés-Lara S, Gomis-Font MA, Fraile-Ribot P, Figuerola J, Lang Y, Franklyn ERT, Lee WL, Zhou J, Zhang Y, Bulitta JB, Boyce JD, Nation RL, Oliver A, Landersdorfer CB. Agyeman AA, et al. Among authors: nation rl. Int J Antimicrob Agents. 2023 Sep;62(3):106887. doi: 10.1016/j.ijantimicag.2023.106887. Epub 2023 Jun 12. Int J Antimicrob Agents. 2023. PMID: 37315906
A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients.
Hanafin PO, Kwa A, Zavascki AP, Sandri AM, Scheetz MH, Kubin CJ, Shah J, Cherng BPZ, Yin MT, Wang J, Wang L, Calfee DP, Bolon M, Pogue JM, Purcell AW, Nation RL, Li J, Kaye KS, Rao GG. Hanafin PO, et al. Among authors: nation rl. Clin Microbiol Infect. 2023 Sep;29(9):1174-1181. doi: 10.1016/j.cmi.2023.05.018. Epub 2023 May 20. Clin Microbiol Infect. 2023. PMID: 37217076 Free article.
Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.
An G, Creech CB, Wu N, Nation RL, Gu K, Nalbant D, Jimenez-Truque N, Fissell W, Patel PC, Fishbane N, Watanabe A, Rolsma S, Kirkpatrick CMJ, Landersdorfer CB, Winokur P. An G, et al. Among authors: nation rl. J Antimicrob Chemother. 2023 Jun 1;78(6):1460-1470. doi: 10.1093/jac/dkad106. J Antimicrob Chemother. 2023. PMID: 37071586 Free PMC article.
357 results